RA
DERM icon

Royce & Associates’s Journey Medical DERM Stock Holding History

Royce & Associates’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,654
Closed -$71.4K – 874
2024
Q2 		$71.4K Hold
12,654
– – ﹤0.01% 861
2024
Q1 		$46.6K Buy
+12,654
New +$55.1K ﹤0.01% 871

Other funds holding DERM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Royce & Associates's DERM Position: Q3 2024 in Review

Royce & Associates sold out of Journey Medical (DERM) in Q3 2024, closing a stake of 12,654 shares — an estimated $71.4K sold.

Royce & Associates first reported a position in DERM in Q1 2024 and held it in 2 quarters. The position peaked at $71.4K in Q2 2024. 36 funds tracked by Wall St. Rank hold DERM as of Q3 2024.

  • Royce & Associates reported no remaining Journey Medical position as of Q3 2024 after selling out during the quarter.
  • Royce & Associates sold 12,654 Journey Medical shares in Q3 2024, an estimated $71.4K.
  • Royce & Associates first reported a position in Journey Medical in Q1 2024 and held it in 2 quarters.
  • Royce & Associates's Journey Medical position peaked at $71.4K in Q2 2024.
  • 36 funds tracked by Wall St. Rank held Journey Medical as of Q3 2024.

Based on Royce & Associates's 13F filing for Q3 2024, filed 6 Nov 2024.